| B7-H1 stimulation activates phosphorylation of JNK and c-jun and down-regulates mitogen-activated protein kinases 1/2 and akt proto-oncogene protein. | unknown |
| Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). | unknown |
| In melanoma cell lines, including BRAFi-resistant cells, PD-L1 expression is variably regulated by oncogenic signaling pathways. | malenoma |
| PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC. | lung |
| TMIT I is associated with a high mutational burden, PD-L1 amplification, and oncogenic viral infection. | unknown |
| PD-L1 expression was significantly associated with wild-type EGFR, and PD-L1 TPS >/=50% seldom overlaps with presence of driver oncogene EGFR. There was no significant difference in PD-L1 expression among the EGFR mutation sites. | unknown |
| The results implied that both squamous and glandular components of adenosquamous carcinoma of the lung may share the same oncogenic driver pathway for carcinogenesis, which is reflected in the patterns of expression of PTEN and PD-L1. | lung |
| DCUN1D1 activated the FAK oncogenic signaling pathway and up-regulated PD-L1. | unknown |
| The present work seeks to assess whether pancreatic carcinomas release exosomes which express c-Met (proto-oncogene mesenchymal-epithelial transition factor) and PD-L1 (programmed cell death 1 ligand 1), and whether the detection of such expression in serum has diagnostic or prognostic meaning for the affected patients. | pancreatic |
| Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. | pancreatic |
| The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth. | breast |
| Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis. | unknown |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. | lung |
| Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. | lung |
| Gliomas can upregulate B7-H1 expression in circulating monocytes and tumor-infiltrative macrophages through modulation of autocrine/paracrine IL-10 signaling, resulting in an immunosuppressive phenotype | glioma |
| This study showed that the brain metastases of small cell lung cancer harbor an active immune microenvironment with presence of various Tumor infiltrating lymphocytes subsets and expression of the immune suppressive molecule PD-L1. | lung |
| Our study demonstrates a cross-talk between PARPi and tumor-associated immunosuppression and provides evidence to support the combination of PARPi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer | breast |
| PERK-p-eIF2alpha pathway could suppress metastasis in triple-negative breast cancer by inhibiting expression of PDL1 and CXCL5 in tumor cells. | breast |
| Study showed that epithelial-mesenchymal transition (EMT) is closely correlated with PD-L1 expression by pancreatic ductal adenocarcinoma cells and with an immunosuppressive tumor microenvironment (TME). These phenomena may occur through IFN-gamma expression from the TME. | pancreatic |
| Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. | glioma |